Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients.
Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.
2018 Hangzhou Zhengxiang, our predecessor, was established to carry out R&D of therapeutics addressing viral infectious diseases, oncology and inflammatory disorders in June.
2019 We initiated the R&D of sebaloxavir marboxil tablets in February.
2020 Our Company was established in May.
2021 We received NMPA approval for the phase 1 clinical trial of sebaloxavir marboxil tablets in September.
2022 We initiated the phase 2 clinical trial of sebaloxavir marboxil tablets in adults with influenza in July.
2023 We entered into an exclusive sales and promotion agreement with Jumpcan Pharmaceutical for sebaloxavir marboxil tablets in August. We received NMPA approval for the phase 3 clinical trial of sebaloxavir marboxil tablets in adolescents (aged 12 to 17) with influenza in August. We completed the phase 3 clinical trial of sebaloxavir marboxil tablets in adults with influenza in October.
2024 The NMPA accepted our NDA for sebaloxavir marboxil tablets in adults with influenza in February. We received NMPA approval for the phase 1 clinical trial of ZX-8177, a major drug candidate, in June.
2025 We received NMPA approval for the phase 3 clinical trial of sebaloxavir marboxil for suspension in children (aged two and older) with influenza in January. The NMPA accepted our NDA for sebaloxavir marboxil tablets in adolescents with influenza in April. We received approval from NMPA for the phase 3 clinical trial of sebaloxavir marboxil tablets for post-exposure prophylaxis in patients (aged five and older) in April. The NMPA approved sebaloxavir marboxil tablets for the treatment of uncomplicated influenza in adults in July. We entered into a license and distribution agreement with Cigalah Medpharm in relation to sebaloxavir marboxil oral formulations, a leading pharmaceutical distributor in the MENA region in July.
Patient-centered, Science-driven, Synergistic teamwork
Co-founder,
Chairman, Executive President
Co-founder,
Chief Scientific Officer
Chief Operating Officer
Senior Vice President, CMC
Senior Vice President, Commercialization
Vice President, Finance
